Hong Kong Stock Alert | YIDU TECH (02158) Surges Over 5% After Winning SMR001 Eye Drop Phase III Clinical Research Project Bid

Stock News

09/24

YIDU TECH (02158) surged over 5%. As of press time, the stock rose 5.39% to HK$6.06, with a turnover of HK$74.9734 million.

On the news front, YIDU TECH announced that its affiliated company Tianjin Happy Life Technology Co., Ltd. recently won the bid for Shandong Yandu Biotechnology Co., Ltd.'s recombinant human nerve growth factor (SMR001) eye drop Phase III clinical research project, with a total project value of approximately RMB 55.82 million.

As China's AI medical transformation driver, YIDU TECH has built a "data-algorithm-scenario" flywheel closed loop based on its independently developed core algorithm engine YiduCore, achieving high-efficiency innovation and low-cost scaled application of AI technology, driving intelligent decision-making to empower the entire industrial chain ecosystem of "medical-pharmaceutical-insurance-patient".

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/1120477928"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1120477928\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1120477928?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-24 11:42","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1120477928","market":"hk","top_or_hot":-1,"title":"Hong Kong Stock Alert | YIDU TECH (02158) Surges Over 5% After Winning SMR001 Eye Drop Phase III Clinical Research Project Bid","media":"Stock News","content":"<p>YIDU TECH (02158) surged over 5%. As of press time, the stock rose 5.39% to HK$6.06, with a turnover of HK$74.9734 million.</p>\n<p>On the news front, YIDU TECH announced that its affiliated company Tianjin Happy Life Technology Co., Ltd. recently won the bid for Shandong Yandu Biotechnology Co., Ltd.'s recombinant human nerve growth factor (SMR001) eye drop Phase III clinical research project, with a total project value of approximately RMB 55.82 million.</p>\n<p>As China's AI medical transformation driver, YIDU TECH has built a \"data-algorithm-scenario\" flywheel closed loop based on its independently developed core algorithm engine YiduCore, achieving high-efficiency innovation and low-cost scaled application of AI technology, driving intelligent decision-making to empower the entire industrial chain ecosystem of \"medical-pharmaceutical-insurance-patient\".</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hong Kong Stock Alert | YIDU TECH (02158) Surges Over 5% After Winning SMR001 Eye Drop Phase III Clinical Research Project Bid</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHong Kong Stock Alert | YIDU TECH (02158) Surges Over 5% After Winning SMR001 Eye Drop Phase III Clinical Research Project Bid\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time smaller\">2025-09-24 11:42</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>YIDU TECH (02158) surged over 5%. As of press time, the stock rose 5.39% to HK$6.06, with a turnover of HK$74.9734 million.</p>\n<p>On the news front, YIDU TECH announced that its affiliated company Tianjin Happy Life Technology Co., Ltd. recently won the bid for Shandong Yandu Biotechnology Co., Ltd.'s recombinant human nerve growth factor (SMR001) eye drop Phase III clinical research project, with a total project value of approximately RMB 55.82 million.</p>\n<p>As China's AI medical transformation driver, YIDU TECH has built a \"data-algorithm-scenario\" flywheel closed loop based on its independently developed core algorithm engine YiduCore, achieving high-efficiency innovation and low-cost scaled application of AI technology, driving intelligent decision-making to empower the entire industrial chain ecosystem of \"medical-pharmaceutical-insurance-patient\".</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"07226","symbol_name":"南方兩倍做多恆科","start_time":0,"source_url":"","article_id":"1120477928","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1120477928","pubTimestamp":1758685339,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"YIDU TECH (02158) surged over 5%. As of press time, the stock rose 5.39% to HK$6.06, with a turnover of HK$74.9734 million. On the news front, YIDU TECH announced that its affiliated company Tianjin...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"07226":"南方两倍做多恒科","HSCEI":"国企指数","BK1189":"医疗保健技术","BK1617":"AI医疗","BK4134":"信息科技咨询与其它服务","02158":"医渡科技","YANG":"三倍做空富时中国ETF-Direxion","BK4614":"Manus概念股","BK1518":"SaaS概念","III":"信息服务"},"translate_title":"港股快讯|医渡科技(02158)大涨超5%中标SMR001滴眼液III期临床研究项目","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02158":1,"07226":1,"HSCEI":1,"III":1,"YANG":1},"content_text":"YIDU TECH (02158) surged over 5%. As of press time, the stock rose 5.39% to HK$6.06, with a turnover of HK$74.9734 million.\nOn the news front, YIDU TECH announced that its affiliated company Tianjin Happy Life Technology Co., Ltd. recently won the bid for Shandong Yandu Biotechnology Co., Ltd.'s recombinant human nerve growth factor (SMR001) eye drop Phase III clinical research project, with a total project value of approximately RMB 55.82 million.\nAs China's AI medical transformation driver, YIDU TECH has built a \"data-algorithm-scenario\" flywheel closed loop based on its independently developed core algorithm engine YiduCore, achieving high-efficiency innovation and low-cost scaled application of AI technology, driving intelligent decision-making to empower the entire industrial chain ecosystem of \"medical-pharmaceutical-insurance-patient\".","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}